Pipeline

Syntimmune is developing new medicines based on our broad understanding of the role of FcRn in human disease, with a specific focus on autoimmune disease.

We are rapidly advancing three drug candidates for a wide variety of conditions. Our lead candidate, SYNT001, is a biologic with high and specific affinity for FcRn that has been optimized to disrupt the interaction between IgG and FcRn. Syntimmune believes SYNT001 shows great promise to treat a wide variety of autoimmune diseases, including hematological, dermatological and neuromuscular conditions.

Stage of Development

 

RESEARCH IND ENABLING PHASE I PHASE Ib/IIa
SYNT001 Autoimmune Disease
SYNT002 Exo- and Endotoxins
SYNT003 Oncology